Sour European markets dent Tate sales
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.TATE AND LYLE, the world's largest starch and sweeteners business, put a brave face on the effect of the 14-year low in the sugar price on its interim results and warned of forthcoming redundancies.
The figures tell a tale of two cycles. Staley, the company's US-based speciality sweeteners business, benefited from lower raw material costs and higher prices. However, the commodity sugar businesses, in particular the European Amylum operation, experienced tough markets.
Group sales fell by pounds 108m, including a pounds 57m currency hit, to pounds 2.1bn. Underlying pre-tax profits rose 10 per cent to pounds 96m, including pounds 5m from asset sales. US sales accounted for 77 per cent of profits.
Larry Pillard, chief executive, said Tate would make UK job cuts as part of a programme to save pounds 15m annually within two years. He stressed the presence in speciality sweeteners - "Our strategy is to add value to carbohydrates" - but the speciality side yields only 30 per cent of profits.
Amylum, which makes starches from potato and wheat, delivered flat profits despite pounds 300m investment. The European sweeteners industry has overcapacity and Tate's rivals are investing in new plant. Yesterday Tate's shares fell 7.5p to 436p as a Italian rival warned of poor trading but still planned to raise capacity. "They're walking into the valley of death in Europe," said David Lang of Investec Henderson Crosthwaite.
Although the capital expenditure benefits are yet to kick in, a turnaround at Amylum depends on European rivals collectively raising prices - unlikely in the next six months. A poor potato harvest this summer would exacerbate Amylum's difficulties.
HSBC Securities forecasts pre-tax profits for the year of pounds 215m and earnings of 32.1p per share. On a long-term view the shares are good value on a forward p/e of 13.5, but do not expect them to skyrocket just yet.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments